No Data
No Data
No Data
No Data
No Data
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein
GlobeNewswireApr 25 19:00
Kymera Therapeutics Initiated at Outperform by Oppenheimer
Kymera Therapeutics Initiated at Outperform by Oppenheimer
Dow JonesApr 22 19:38
Kymera Therapeutics (KYMR.US) was first covered by Oppenheimer, giving it an superior market rating, with a target price of $53.00.
Kymera Therapeutics (KYMR.US) was first covered by Oppenheimer, giving it an superior market rating, with a target price of $53.00.
Zhitong FinanceApr 22 19:31
Oppenheimer Initiates Coverage On Kymera Therapeutics With Outperform Rating, Announces Price Target of $53
Oppenheimer analyst Jeff Jones initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announces Price Target of $53.
BenzingaApr 22 19:28
Kymera Therapeutics Reveals Preclinical Data on Cancer-Fighting Drug KT-333 at AACR Meeting
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new
BenzingaApr 8 19:05
Kymera Therapeutics(KYMR.US) Director Sells US$5.13 Million in Common Stocks
$Kymera Therapeutics(KYMR.US)$ Director Booth Bruce sold 127.54K shares of Common Stocks on Mar 14, 15, 2024 at an average price of $40.25 for a total value of $5.13 million.Source: Announcement What
Futu NewsMar 16 08:05
No Data
No Data